Stay Informed
Precision oncology provides a unique opportunity to improve clinical outcomes1
Benefits of precision oncology
From 2006 to 2018, there was a 7x increase in the number of patients estimated to benefit from genome-based therapy2
Precision oncology benefits
- Significant improvements in ORR, PFS, and QOL for certain well-characterized molecular alterations with available targeted therapies compared with conventional chemotherapies3-5
- Potentially avoids cycles of trial and error and associated adverse physical and financial impact6
aWhen adjusted for age, sex, histologic diagnosis, and number of previous lines of treatment.7
The data-driven difference
Targeting genomic alterations can potentially lead to better outcomes for patients1
OS based on availability of molecular test results before 1L therapy (mNSq, NSCLC)8,b
bRetrospective data collected between January 1, 2019, and December 31, 2020.
OS in pancreatic cancer with matched vs unmatched therapy9
In both studies, OS was improved in patients who received therapies directed toward their specific alterations.8,9
Key genomic alterations
Point mutations and pathogenic gene fusions are among the most common genomic alterations driving cancer10
Point mutations
(eg, KRAS, BRAF, and EGFR) are changes in DNA base pair(s)11,12
(eg, KRAS, BRAF, and EGFR) are changes in DNA base pair(s)11,12
Pathogenic gene fusions
(eg, ALK, NTRK, ROS1, MET, and NRG1) typically occur when 2 different genes join to form an abnormal hybrid gene12-14
(eg, ALK, NTRK, ROS1, MET, and NRG1) typically occur when 2 different genes join to form an abnormal hybrid gene12-14
Click and drag the bar to compare
Pathogenic Gene Fusion
Cancer
Point Mutation
Cancer
Point Mutation
Pathogenic Gene Fusion
What difference can targeting pathogenic gene fusions make for your patients?
See the data
1L, first-line; HR, hazard ratio; IQR, interquartile range; mNSq, metastatic non-squamous; NSCLC, non–small cell lung cancer; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; QOL, quality of life.
References: 1. Zhao S, Zhang Z, Zhan J, et al. Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer. BMC Med. 2021;19(1):223. doi:10.1186/s12916-021-02089-z 2. Marquart J, Chen EY, Prasad V. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol. 2018;4(8):1093-1098. doi:10.1001/jamaoncol.2018.1660 3. Shin DH, Lee D, Hong DW, et al. Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung. Oncotarget. 2016;7(43):69450-69465. doi:10.18632/oncotarget.11913 4. Doroshow DB, Doroshow JH. Genomics and the history of precision oncology. Surg Oncol Clin N Am. 2020;29(1):35-49. doi:10.1016/j.soc.2019.08.003 5. Lassen UN, Makaroff LE, Stenzinger A, et al. Precision oncology: a clinical and patient perspective. Future Oncol. 2021;17(30):3995-4009. doi:10.2217/fon-2021-0688 6. Personalized Medicine Coalition. The Personalized Medicine Report 2020: Opportunities, Challenges, and the Future. Accessed February 7, 2023. www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/PMC_The_Personalized_Medicine_Report_Opportunity_Challenges_and_the_Future.pdf 7. Haslem DS, Van Norman SB, Fulde G, et al. A retrospective analysis of precision medicine outcomes in patients with advanced cancer reveals improved progression-free survival without increased health care costs. J Oncol Pract. 2017;13(2):e108-e119. doi:10.1200/JOP.2016.011486 8. Aggarwal C, Marmarelis ME, Hwang W, et al. Association between availability of molecular genotyping results and overall survival in patients with advanced nonsquamous non–small-cell lung cancer. JCO Precis Oncol. 2023;7:e2300191.doi:10.1200/PO.23.00191 9. Pishvaian MJ, Blais EM, Brody JR, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol. 2020;21(4):508-518. doi:10.1016/S1470-2045(20)30074-7 10. Zhang R, Dong L, Yu J. Concomitant pathogenic mutations and fusions of driver oncogenes in tumors. Front Oncol. 2021;10:544579. doi:10.3389/fonc.2020.544579 11. Gunter C. Point mutation. National Human Genome Research Institute. Updated February 3, 2023. Accessed February 7, 2023. https://www.genome.gov/genetics-glossary/Point-Mutation 12. Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020;12(1):8. doi:10.1186/s13073-019-0703-1 13. Drilon A, Duruisseaux M, Han J-Y, et al. Clinicopathologic features and response to therapy of NRG1 fusion–driven lung cancers: the eNRGy1 Global Multicenter Registry. J Clin Oncol. 2021;39(25):2791-2802. doi:10.1200/JCO.20.03307 14. Latysheva NS, Babu MM. Discovering and understanding oncogenic gene fusions through data intensive computational approaches. Nucleic Acids Res. 2016;44(10):4487-4503. doi:10.1093/nar/gkw282